ArticleJTO clinical and research reports2026
Oncological Outcomes of Complete Versus Limited Thymectomy in Early Stage Thymic Epithelial Tumors: A Systematic Review and Individual Patient Data Meta-Analysis.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To clarify the role of limited versus complete thymectomy in stage I thymic epithelial tumors (TETs) using standardized survival measures and predefined oncological outcomes. Methods: An individual patient data (IPD) meta-analysis of studies investigating complete versus limited thymectomy for stage I TETs was conducted. IPD was extracted from published Kaplan-Meier curves using the IPDfromKM method.Primary end point of the study was freedom from recurrence (FFR) in complete versus limited thymectomy. Secondary end points were time to progression (TTP), overall survival, recurrence rate in the overall population and stratified per Masaoka-Koga stage, and survival measures according to resection extension (thymomectomy alone versus hemi-thymectomy versus subtotal thymectomy).Hazard ratios and relative 95% confidence intervals (95% CIs) were estimated with Cox regression analyses. Odds ratio (OR) with 95% CI was used to derive categorical variables. Results: Overall, IPD from 2314 patients (1434 complete thymectomy and 880 limited thymectomy) from seven retrospective studies were retrieved.For FFR, IPD were extracted from three studies including 307 patients receiving complete thymectomy (n = 178) and limited thymectomy (n = 129). Median follow-up was 55.7 months (95% CI 52.3-59). The 10-year FFR for complete versus limited thymectomy was 90.2% versus 92.1%, respectively.No differences were found in TTP, overall survival, and recurrence rate in the two groups.In those patients presenting a Masaoka-Koga stage II disease, OR for recurrence favored complete than limited thymectomy ( Conclusion: No evidence favored limited than complete thymectomy in early stage TET treatment according to standardized survival measures. However, in Masaoka-Koga stage II disease, complete thymectomy demonstrated lower recurrence rate. Finally, among patients receiving limited thymectomy, thymomectomy alone leads to worse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.